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The discovery of RNA interference (RNAi), 1 an innate biological process through which the expression of specifically targeted genes can be modulated and/or silenced, ushered in a new world of research and potential therapeutic applications thereby setting the stage for a paradigm shift in oncology. Targeted gene knockdown can be used as a preclinical tool for reverse genetics to determine the function of a given gene as well as delineating its functional connectivity. In the therapeutic arena, the potential of targeted therapy with high specificity can finally be considered a realizable goal. The effect of RNAi and associated technical advances on the scientific community is attested to by more than 20 000 related publications in the PubMed database. A number of in vivo animal studies have shown the activity of RNAi technology implying likely potential for therapeutic efficacy in humans; in fact, a few RNAibased therapeutic strategies are currently being tested through clinical trials. 2 RNA interference holds strong promise for cancer gene therapy where differentially expressed genes, designated as malignancy process-dependent (drivers 3, 4 ) by virtue of high connectivity and, most likely, 'in-betweenness', can be targeted as a presumptive, individual tumor's 'Achilles' heel'. 5 RNAi can be effected through two types of molecules; a synthetic small interfering RNA (siRNA) and a vector-based short hairpin RNA (shRNA). siRNAs are 21-23 nucleotide (nt), double-stranded RNAs with 2-nt overhangs on the 3 0 ends capable of being incorporated into an RNA-induced silencing complex, whereas shRNAs are composed of RNA folded into stem-loop structures similar to pre-miRNA hairpins requiring processing by DICER before incorporation into the RNA-induced silencing complex. Although both siRNA and shRNA are reported to be able to achieve target-specific silencing, insofar as they are mechanistically different, one could postulate varying levels of therapeutic effectiveness based on considerations of both silencing efficiency and off-target effects (as a safety parameter).
Soon after the discovery, in fact, the dream of target specificity was somewhat dampened by the finding of offtarget effects associated with the applications of RNAi. Induction of interferon in cells transfected with siRNA was the first reported off-target effect of RNAi. siRNA duplexes longer than 29-30 bp can readily induce a cellular interferon response similar to double-stranded RNA. However, structural modification or shortening the length of the siRNA in large part abrogates interferon induction. 6 There are also recent reports of siRNA-or shRNA-induced stimulation of Toll-like receptors (TLRs) including the membrane-bound TLR4 and endosomal TLR3 (dsRNA), TLR7 and 8 (ssRNA) and TLR9 (unmethylated CpG), and downstream immune (including interferon) responses. 7 The use of unmethylated CpGfree plasmid or minimal plasmid vector attenuates this potentially toxic effect.
A recent murine study has shown that shRNA expression driven by highly active RNA polymerase III type promoters (U6 or H1) delivered through liverdirected adeno-associated virus can result in significant lethality. The lethality did not appear to be target or sequence specific but was dose dependent. 8 This effect was later found to be caused by overexpression of shRNA saturating the endogenous miRNA pathway, particularly the exportin-5-mediated nuclear export and the downstream RNA-induced silencing complex component, Argonaute-2, 9 resulting in excess and toxic concentrations of shRNA competing with endogenous miRNAs. This lethal effect was alleviated by the use of an RNA polymerase II promoter-driven shRNA expression cassette that does not overwhelm the miRNA pathway and exportin-5-mediated nuclear export and allows for greater regulation. 10 All RNAi-based therapeutics have off-target effects that impact transcript expression and translation resulting in off-target phenotypes.
11 siRNAs can act similarly to miRNAs as a result of complementarity of their seed region sequence (positions 2-7) to unintended mRNA sites producing off-target effect in a dose-responsive manner. 12 This 'miRNA type' of off-target effect is elicited by both the passenger strand and the guide strand. In addition, short mismatches between siRNA sequence and unintended mRNA sequences can result in off-target knockdown. Chemical modification of the seed region sequence of the guide strand (particularly position 2) significantly improves target specificity. 13 Comparison of the off-target effects of siRNA to shRNA has uncovered differences in gene expression profiles produced by siRNA and shRNA effectors with identical nucleotide targeting sequences. In general, when induced from an integrated vector, shRNA produces less up-and downregulation of off-target transcripts than a corresponding siRNA dosed to achieve a comparable level of target knockdown (M Mehaffey, T Ward and M Cleary, in preparation, Figure 1 ). This difference in off-target activity of shRNA in comparison with siRNA is likely related to mechanistic differences in the manner in which these molecules enter the RNAi pathway.
14 Using RNA polymerase II promoter, the primary transcript of shRNA is polyadenylated, similar to pri-miRNA hairpins and initially processed in the nucleus by complex with Drosha/DGCR8 and, therefore, subject to normal cellular regulatory processes of nuclear export and RNA-induced silencing complex loading in the cytoplasm. 15 In contrast, siRNA, which is not integrated into nuclear and early cytoplasmic processing and requires higher concentrations and more frequent dosing to achieve similar levels of knockdown, is more likely to result in off-target effects. In addition, unprotected siRNA in the cytoplasm may be more susceptible to degradation and metabolic processes, which may further contribute to nonspecific target recognition. Some researchers have taken a further step to alleviate toxicity and enhance specificity by embedding shRNA sequences into miRNA contexts, such as the miR-30 stem loop precursor, to create artificial primiRNA transcripts. 16 It remains to be seen whether such an approach has an impact on the overall off-target regulations caused by shRNA.
As our understanding of the RNAi process expands and criteria for higher affinity and target-specific effectors broaden, the potential of a paradigm shift in oncological therapeutics becomes a more foreseeable reality. Identification and elucidation of direct (sequence-related) and indirect (immune-mediated) off-target effects has lead to modifications in product design and targeting strategy. Indeed, improvements in the targeted delivery of stable RNAi effectors will further augment the specificity and selectivity of the process and extend the application of RNAi-based therapeutics from localized to systemic diseases. Despite the highly publicized in vivo miRNA-related toxicity of shRNA (discussed above), which was initially perceived as a strong deterrent to its clinical application, shRNA has several advantages over siRNA: fewer off-target effects, multiple target silencing capacity without a corresponding increase in dose, durability of effect and inducible application. When integrated with an effective delivery system, there are compelling data to support implementation of shRNA as a next generation therapeutic strategy for cancer.
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